Post Mortem Analysis of a Left Atrial Appendage Occlusion Device (PLAATO) in a Patient with Permanent Atrial Fibrillation

2005 ◽  
Vol 14 (1) ◽  
pp. 17-20 ◽  
Author(s):  
Heyder Omran ◽  
Harald Schmidt ◽  
David Hardung ◽  
Christoph Hammerstingl ◽  
Giso von der Recke ◽  
...  
2020 ◽  
Vol 4 (1) ◽  
pp. 1-5
Author(s):  
Andre Briosa e Gala ◽  
Andrew Cox ◽  
Michael Pope ◽  
Timothy Betts

Abstract Background Caring for athletes with cardiac disease requires an approach that caters to the specific needs of the athlete. Case summary A 27-year-old professional rugby player was admitted with decompensated heart failure and atrial fibrillation (AF). Transthoracic echocardiogram showed features in keeping with a dilated cardiomyopathy with severe left ventricular (LV) systolic impairment. He made good progress on evidence-based heart failure medication and his LV systolic function returned to normal. He failed to maintain sinus rhythm with cardioversion and remained in persistent AF. He then suffered a transient ischaemic attack despite appropriate anticoagulation. At 1-year follow-up, he was asymptomatic and against medical advice continued to play competitive rugby whilst taking rivaroxaban. He subsequently underwent implantation with a percutaneous left atrial appendage occlusion device, allowing him to discontinue anticoagulation, reduce his bleeding risk and resume his career, whilst simultaneously lowering the thromboembolic risk. Discussion Counselling should include different management options aimed at minimizing the risks to athletes if they to return to competitive sports. Left atrial appendage occlusion devices are a suitable AF-related stroke prevention strategy in athletes competing in full-contact sports.


2012 ◽  
Vol 53 (1) ◽  
pp. 83 ◽  
Author(s):  
Yung Ly Kim ◽  
Boyoung Joung ◽  
Young Keun On ◽  
Chi Young Shim ◽  
Moon Hyoung Lee ◽  
...  

1970 ◽  
Vol 1 (1) ◽  
pp. 64-71
Author(s):  
M Ullah ◽  
N Kar ◽  
PK Karmaker ◽  
S Alam ◽  
MS Mamun ◽  
...  

Cerebro-vascular Disease (CVD) is the third most common cause of death in developed world after cancer and IHD. Atrial fibrillation (AF) is responsible in 45% of cases cardioembolism leading to CVD. Atrial fibrillation is considered to be one of the growing cardiovascular epidemics in the 21st century. Warfarin is a proven drug for prevention of stroke in patients with atrial fibrillation. Newer anticoagulants are being tried, fibrillation. Newer anticoagulants are being tried, but not yet well established by clinical trials. Separation of left atrial appendage from circulation by surgery or device implantation is a promising one in this field. Key words: Atrial fibrillation, Stroke, Left atrial appendage occlusion device DOI: http://dx.doi.org/10.3329/cardio.v1i1.8217 Cardiovasc. j. 2008; 1(1) : 64-71


Sign in / Sign up

Export Citation Format

Share Document